Before revenue, before hiring, one set of decisions shapes your German operation for years: the legal vehicle, the holding structure and the tax setup. Get them right up front and the rest compounds; get them wrong and you restructure — expensively.
Most foreign investors operate through a German GmbH (limited company), sometimes under a holding for tax efficiency. Company profits face corporate income tax plus municipal trade tax — a combined effective rate around ~30% — and VAT is 19%. Holdings benefit from a near-full participation exemption on qualifying dividends and gains; financing, profit repatriation and permanent-establishment risk all turn on the structure you pick. And if you're operating in a regulated field like pharma, the entity choice also carries your regulatory obligations — so structure and compliance have to be designed together.
Germany rewards deliberate setup. The vehicle and holding you choose determine your tax rate, your liability, your ability to move profits home, and how easily you can grow or exit.
These are not decisions to reverse cheaply: changing the structure later can trigger tax, contractual and regulatory friction. For an operating investment — not just a passive stake — the right answer aligns the legal vehicle, the tax position and the operational plan from day one.
You can change your marketing in a quarter. Changing your holding structure is a project of its own.
Germany offers a range of vehicles. For an operating business, the choice is usually between a GmbH and, for smaller or partnership setups, its alternatives.
For groups, a German or EU holding above the operating company can be highly tax-efficient.
Under the participation exemption, qualifying dividends and capital gains a corporation receives from shareholdings are roughly 95% tax-exempt (5% treated as non-deductible expense). Combined with Germany's extensive double-tax-treaty network and the EU Parent-Subsidiary Directive, this lets profits move up the chain and dividends flow home with limited leakage — if the structure is set up correctly.
The trade-offs are substance and anti-avoidance rules: a holding needs genuine substance to hold up, and treaty benefits can be denied to purely artificial arrangements. Structure for efficiency, but build real substance.
For a pharma, medtech or diagnostics operation, the German entity isn't just a tax vehicle — it often has to be the one that holds the marketing authorization, employs or contracts the graduated-plan officer (Stufenplanbeauftragter) and information officer, signs distribution and rebate agreements, and acts as your local representative to authorities.
That means the structure decision and the compliance setup can't be designed separately. A GmbH is usually the natural home for an operating affiliate that will carry these duties — and the timing has to line up with your authorization and launch plan, not follow it. This is where a generic tax structure and a life-sciences market-access plan have to meet in the middle.
See our note on the pharmacovigilance & GxP obligations your German entity would carry.
In a focused session we map the right vehicle and holding for your case, flag the PE and transfer-pricing risks, and — if you're in life sciences — line the structure up with the regulatory and market-access setup. We own the commercial read and coordinate the tax and legal specialists.